SyntheticGestalt, Enamine partner to develop AI-based drug discovery model
The partnership is intended to develop a suite of AI models to generate synthetically accessible biologically active compounds…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
12 Jan 24
The partnership is intended to develop a suite of AI models to generate synthetically accessible biologically active compounds…
12 Jan 24
Illumina Ventures Labs is well positioned to enable early-stage companies to accelerate the time needed to reach their…
12 Jan 24
Approach leverages novel mechanisms such as remyelination and anti-neuroinflammation to address a broad spectrum of degenerative CNS diseases
11 Jan 24
WuXi Biologics will grant exclusive rights to the investigational monoclonal antibodies to BioNTech in exchange for an upfront…
11 Jan 24
Under the alliance, Japanese Foundation for Cancer Research will become a valued member of Parexel's Global Site Alliance…
11 Jan 24
XeriJect formulations are innovative, ready-to-use, viscoelastic pharmaceutical suspensions that have the potential to improve drug delivery, lower treatment…
11 Jan 24
Collaboration Aims to Improve Patient Experience, Accessibility and Efficiency in Decentralized Clinical Trials
10 Jan 24
The acquisition expands GSK’s respiratory pipeline with AIO-001, a phase 2-ready, long-acting antibody targeting the clinically validated TSLP…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
10 Jan 24
The Danaher-IGI Beacon for CRISPR Cures centre will use CRISPR-based gene editing technology to drive pre-clinical gene-editing therapies…
09 Jan 24
Through the acquisition, Johnson & Johnson will benefit from Ambrx’s portfolio of clinical and preclinical programmes, including lead…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates